Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | USP30 | Q70CQ3 | 7/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | UCHL1 | P09936 | 4/20 | 0.45 |
| ▸ | SCN4A | P35499 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25395953 | 1.00 | HSD17B10 (0.53) | HSD17B10SMN1; SMN2NPC1USP30LMNA | |
| SCHEMBL1256351 | 1.00 | HSD17B10 (0.53) | HSD17B10SMN1; SMN2NPC1USP30LMNA | |
| SCHEMBL1584759 | 1.00 | HSD17B10 (0.53) | HSD17B10SMN1; SMN2NPC1USP30LMNA | |
| SCHEMBL1257155 | 0.96 | HSD17B10 (0.49) | HSD17B10SMN1; SMN2NPC1USP30LMNA | |
| SCHEMBL1250737 | 0.96 | HSD17B10 (0.49) | HSD17B10SMN1; SMN2NPC1USP30LMNA | |
| SCHEMBL5328715 | 0.96 | HSD17B10 (0.49) | HSD17B10SMN1; SMN2NPC1USP30LMNA | |
| SCHEMBL31048243 | 0.94 | HSD17B10 (0.48) | HSD17B10SMN1; SMN2NPC1USP30LMNA | |
| SCHEMBL1584930 | 0.92 | HSD17B10 (0.47) | HSD17B10SMN1; SMN2NPC1USP30LMNA | |
| SCHEMBL444365 | 0.91 | HSD17B10 (0.43) | HSD17B10SMN1; SMN2NPC1USP30LMNA | |
| SCHEMBL2096289 | 0.91 | HSD17B10 (0.43) | HSD17B10SMN1; SMN2NPC1USP30LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 157 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023176867-A1 | METHOD FOR PRODUCING 2-ACETYL-1-PYRROLINE | 日清食品ホールディングス株式会社 | 2023-09-21 | — | — | WO | claimed |
| US-20260008758-A1 | LINEAR DIPEPTIDYL PEPTIDASE 1 INHIBITORS AND USES THEREOF | INSMED INCORPORATED | 2026-01-08 | — | — | US | disclosed |
| US-20250313553-A1 | ANNULATED 2-AMINO-3-CYANO THIOPHENES AND DERIVATIVES FOR THE TREATMENT OF CANCER | BOEHRINGER INGELHEIM INTL GMBH CORP (DE) | 2025-10-09 | — | — | US | disclosed |
| WO-2025108342-A1 | AROMATIC RING-FUSED THIAZINE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | 杭州百诚医药科技股份有限公司 | 2025-05-30 | — | — | WO | disclosed |
| EP-4441050-A1 | ANNULATED 2-AMINO-3-CYANO THIOPHENES AND DERIVATIVES FOR THE TREATMENT OF CANCER | Boehringer Ingelheim International GmbH (DE) | 2024-10-09 | — | — | EP | disclosed |
| EP-4425181-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | Bertis Inc (KR) | 2024-09-04 | — | — | EP | disclosed |
| US-20240142876-A1 | SEMICONDUCTOR SUBSTRATE MANUFACTURING METHOD AND COMPOSITION | JSR CORPORATION (JP) | 2024-05-02 | — | — | US | disclosed |
| CN-112812128-B | Macrocyclic compounds as ALK and ROS modulators | 正大天晴药业集团股份有限公司 | 2024-04-02 | — | — | CN | disclosed |
| US-20240105451-A1 | SEMICONDUCTOR SUBSTRATE MANUFACTURING METHOD AND COMPOSITION | JSR CORPORATION (JP) | 2024-03-28 | — | — | US | disclosed |
| US-20240011979-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTES | BERTIS INC. (KR) | 2024-01-11 | — | — | US | disclosed |
| US-6878736-B1 | Histamine H3 receptor ligands | JAMES BLACK FOUNDATION LIMITED (GB) | 2005-04-12 | — | — | US | disclosed |
| US-20040180887-A1 | N-aroyl cyclic amine derivatives as orexin receptor antagonists | SMITHKLINE BEECHAM LIMITED (GB) | 2004-09-16 | — | — | US | disclosed |
| US-20040167128-A1 | Sulfonamides having antiangiogenic and anticancer activity | ABBVIE INC. | 2004-08-26 | — | — | US | disclosed |
| US-20040157836-A1 | Sulfonamides having antiangiogenic and anticancer activity | ABBOTT LABORATORIES | 2004-08-12 | — | — | US | disclosed |
| WO-2004041795-A1 | NOVEL INHIBITORS OF DIPEPTIDYL PEPTIDASE IV | GUILFORD PHARMACEUTICALS INC. (US) | 2004-05-21 | — | — | WO | disclosed |
| WO-2004033419-A1 | SULFONAMIDES HAVING ANTIANGIOGENIC AND ANTICANCER ACTIVITY | ABBOTT LABORATORIES (US) | 2004-04-22 | — | — | WO | disclosed |
| EP-1056733-A1 | HISTAMINE H3 RECEPTOR LIGANDS | JAMES BLACK FOUNDATION LIMITED (GB) | 2000-12-06 | — | — | EP | disclosed |
| WO-1999042458-A1 | HISTAMINE H3 RECEPTOR LIGANDS | JAMES BLACK FOUNDATION LIMITED (GB) | 1999-08-26 | — | — | WO | disclosed |
| US-5686565-A | ANTIINFLAMMATORY AGENTS | SCIOS INC. (US) | 1997-11-11 | — | — | US | disclosed |
| US-5552383-A | ANALGESIC, ANTIINFLAMMATORY FOR WOUNDS | SCIOS NOVA INC. (US) | 1996-09-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040180887-A1 | N-aroyl cyclic amine derivatives as orexin receptor antagonists | HCRTR2, HCRTR1, OXTR | HSD17B10 969/4885SMN1; SMN2 2856/4885NPC1 799/4885 |
| US-20250313553-A1 | ANNULATED 2-AMINO-3-CYANO THIOPHENES AND DERIVATIVES FOR THE TREATMENT OF CANCER | KRAS, NRAS, TP53 | HSD17B10 4874/4885SMN1; SMN2 3654/4885NPC1 3943/4885 |
| US-20040167128-A1 | Sulfonamides having antiangiogenic and anticancer activity | METAP2, METAP1, DNPEP | HSD17B10 3758/4885SMN1; SMN2 1949/4885NPC1 4400/4885 |
| US-20040157836-A1 | Sulfonamides having antiangiogenic and anticancer activity | METAP2, METAP1, DNPEP | HSD17B10 3758/4885SMN1; SMN2 1949/4885NPC1 4400/4885 |
| US-20260008758-A1 | LINEAR DIPEPTIDYL PEPTIDASE 1 INHIBITORS AND USES THEREOF | DPP3, DPP7, DPP9 | HSD17B10 148/4885SMN1; SMN2 1910/4885NPC1 184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.